MedTrace Logo

Heparin for Pregnant Women With Thrombophilia

NCT01019655 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2009-11-25

No results posted yet for this study

Summary

The purpose of this study is to investigate whether heparin is an effective treatment in pregnant women at risk for thrombosis and other pregnancy-associated complications.

Conditions

  • Pregnancy and Thrombophilia

Interventions

DRUG

Nadroparin calcium

nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Clemens B Tempfer, MD · University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-01-31
Completion
2012-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01019655 on ClinicalTrials.gov